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changed therapy. In the oral treatment group 32% of patients are adherent to
their first-line treatment and 54% have changed treatment. Probabilistic-sensi-
tivity-analyses demonstrated the robustness of the model regarding assump-
tions and input-parameters. CONCLUSIONS: A treatment switch to Paliperidone
palmitate is a cost-effective alternative, improves treatment adherence and
reduces health-care costs in the future and leads to higher quality-of-life.
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OBJECTIVES: Despite of the controversy of antidepressant use during the gesta-
tional period, the reported antidepressant use at any time during pregnancy has
increased. This study aimed to explore antidepressant use behavior (persis-
tence) in low income, insured pregnant women in U.S. METHODS: This retro-
spective study using South Carolina Medicaid claims data (2004-2009) identified
eligible pregnant women (18 years) who were diagnosed with depression and
filled at least two antidepressant prescriptions during pregnancy. Type of anti-
depressant prescribed for pregnant women, length of therapy, antidepressant
use history before pregnancy, and trimester of antidepressant initiation were
measured to describe antidepressant use patterns. Our main outcome measure
was persistence with antidepressant therapy during pregnancy. Failure to per-
sist was defined as having a gap between two consecutive prescriptions of at
least 15 days. A Cox regression model was applied to identify predictors asso-
ciated with the risk for non-persistence with antidepressants in pregnant
women. RESULTS: Of 804 pregnant women meeting the study criteria, 78% took
selective serotonin reuptake inhibitors (SSRIs) during pregnancy, 39% had his-
tory of antidepressant use during 1 year before pregnancy, and less than 40%
initiated therapy during the first trimester. The average length of antidepres-
sant therapy during pregnancy was 114 days. Nearly 55% of women were per-
sistent without a gap ( 15 days) after initiation of antidepressant therapy.
Black women were 33% more likely to be non-persistent with antidepressants
during pregnancy than white women. Women with history of antidepressant
use during 1 year before pregnancy were 44% more likely to be non-persistent
with the therapy. CONCLUSIONS: Persistence with antidepressants was poor
during pregnancy in low income, insured pregnant women. Further studies are
needed to examine associations between persistence with antidepressants dur-
ing pregnancy and maternal and newborn outcomes.
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OBJECTIVES: To give a literature review and assess the health status utility and
productivity of adult patients with attention-deficit/hyperactivity disorder
(ADHD) focusing on measures with outstanding importance for health eco-
nomic analysis. METHODS: PubMed was systematically reviewed for adult
ADHD studies involving the EQ-5D and/or Work Productivity and Activity Im-
pairment (WPAI) questionnaires. A cross sectional survey in an outpatient psy-
chiatry centre was performed and the Clinical Global Impression scale (CGI-S)
was used to categorize patients by severity. RESULTS: While several studies
assessed the impact of ADHD in childhood only one (Patient 2011;4(4):247-57)
dealt with EQ-5D in adult patients and none applied WPAI. In our survey, forty-
four patients (males 79.5%) were involved with mean (SD) age of 30.0 (9.9) years
and disease duration of 7.6 (6.6) years. Thirty-three (75%) were singles, 9 (20.5%)
married (20.5%), 2 (4.5%) divorced and 9 (20.5%) had children. Highest educa-
tional level was primary, secondary school and university at 5 (11.4%), 22 (50.0%)
and 17 (38.7%) cases, respectively. Twenty-nine (65.9%) were taking medication
for ADHD, seven (15.9%) needed accompanying person when travelling for
health care. Injury requiring medical care occurred at 6 (13.6%) patients, 4 re-
lated to ADHD by self-report. Usual activities, pain/discomfort and anxiety/
depression were the most affected EQ-5D dimensions (moderate problem:
52.3%, 47.7%, 54.5%) and the EQ-5D score (mean 0.747, SD 0.280) was signifi-
cantly lower than the age-matched population norm (p0.05). Utility in mild
(CGI-S3) and moderate (CGI-S4) health state was 0.799 and 0.706, respec-
tively. Twenty-three (52.3%) patients were working, 17 (38.6%) were students
and 4 (9.1%) unemployed. WPAI results were as follows, mean (SD): absenteeism
0.1 (0.3)%, presenteeism 33.0 (26.2)%, overall work impairment 16.9 (22.8)%, ac-
tivity impairment 39.5 (28.7)%. CONCLUSIONS: Health status utility and produc-
tivity in adult ADHD is underexplored. Our study suggests that impaired every-
day activities and preseenteism are considerable and deserve further research.
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OBJECTIVES: To assess preferences, using the time trade-off (TTO), regarding fre-
quencies of having to go for a doctor’s visit to receive pharmacological injections
for the treatment of schizophrenia.METHODS:A survey was conducted in Sweden;
respondents including 259 patients with a serious mental disorder, 263 relatives of
individuals suffering from a serious mental disorder, and 528 people sampled from
the general population were recruited for the purpose of this study. A time trade-
off (TTO) study design was used to elicit the utility of decreasing the frequency of
necessary doctor visits. Average utilities were calculated for each health state for
each respondent group. The marginal disutility of an additional yearly visit to the
doctor was estimated using a standard OLS regression with an intercept. Bootstrap-
ping was utilized to compute 95% confidence intervals around utilities and mar-
ginal disutilities. RESULTS: The marginal disutility of an additional doctor visit was
found to be 0.0041 for patients, 0.0022 for relatives, 0.0017 for the general popula-
tion and 0.0022 for an average respondent. For an average respondent across all
groups, this corresponded to an additional utility of 0.031 between having to visit
the doctor for an injection once a month versus every other week and 0.048 be-
tween having to visit the doctor for an injection once every 3 months versus every
other week. CONCLUSIONS: The results are suggestive of a general trend of in-
creased reported disutility for a higher number of doctor visits for an injection per
year across all respondent groups.
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OBJECTIVES: To systematically identify and review published evidence on health-
state utility weights in paediatric and adolescent ADHD.METHODS:Utility weights
were identified as part of a wider systematic review, which was performed to
identify input parameter values for an economic model in ADHD. PubMed, EM-
BASE, Cochrane National Health Service’s Economic Evaluation Database, EconLit,
and Health Economic Evaluations Database were searched from 1960 to May 2011.
The review focused on articles reporting utility weights in ADHD by level of treat-
ment response. RESULTS: A total of 1,648 unique titles and abstracts were re-
trieved; 1,630 records were excluded upon title (or abstract) review and 12 upon
full-text review. The review included 6 studies reporting utilities by level of re-
sponse, 2 of which further stratified utilities by treatment type. One study reported
utilities for 4 health states (‘normal’, ‘borderline to mildly ill’, ‘moderately to mark-
edly ill’, and ‘severely ill’). One study used the EQ-5D instrument completed by
parents; 2 assessed parents’ preferences using standard gamble; 1 used statistical
mapping (for responder and nonresponder states) and time trade-off (TTO) inter-
views and visual analogue scales (for 4 disease-severity health states); 1 calculated
scores from other utility studies; and 1 did not report methods explicitly. Utilities
for responders ranged between 0.98 and 0.80; utilities for non-responders ranged
between 0.93 and 0.70. TTO-derived utilities for the 4 health states were rated by
members of the general public and ranged from 0.839 (’normal’) to 0.444 (’severely
ill’). The review assessed the methodological compliance of each included study
with NICE Reference Case. CONCLUSIONS: Our review identified utility estimates
potentially suitable for use in ADHD economic evaluations. Appropriateness of
these for inclusion in a particular analysis needs to be assessed in terms of the
modelled heath states and the clinical outcomes used to define these.
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OBJECTIVES: To validate the clinically useful depression outcome scale (CUDOS)
for evaluating the severity of depressive symptoms in patients with major depres-
sive disorder (MDD) attending a Primary Care Service. METHODS: An epidemiolog-
ical, cross-sectional, multicentre study was conducted including adult patients
diagnosed as MDD according to the DSM-IV TR during the last 3 months. The
following instruments were applied: Primary Care Evaluation of Mental Disorders
(PRIME-MD), Hamilton Rating Scale for Depression (HAMD-17), CUDOS, Social and
Occupational Functioning Assessment Scale (SOFAS), SF-36 (Physical –PCS- and
Mental –MCS- Component Summaries) and the Clinical global Impression for Se-
verity of Illness (CGI-SI). CUDOS feasibility, internal consistency (Cronbach=s ),
convergent validity (Spearman correlation with SOFAS, HAMD-17 and SF-36) and
discriminant validity (differences in CUDOS values according to HAMD-17 classifi-
cation of severity and the CGI-SI: Kruskal-Wallis and Mann-Whitney U –Bonferroni
correction-) were evaluated. Finally, a cut-off score (Receiver Operation Curve-
ROC- analysis) was calculated using the HAMD-17 as criterion (0-7 remission).
RESULTS: In total, 305 MDD patients with a mean age (SD) of 51.75 (15.53) years
(30.5% males) were interviewed. According to the HAMD-17, 7.9% of patients were
in remission, 29.8% suffered from mild depression, 22.0% moderate depression,
21.0% severe and 19.3% very severe. Mean(SD) time for completion was 4.47(2.4)
minutes and floor or ceiling effects were found in less than 1% of patients. Cron-
bach=s  was high (0.877). Correlations with CUDOS were: -0.402(SOFAS),
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